Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention
Executive Summary
Foreign tablets, active pharmaceutical ingredient residues and failed line clearance plagued operations at repackers that received FDA warning letters in FY 2023.
You may also be interested in...
The Long Learning Curve For Artificially Intelligent Drug Manufacturing Begins Now
Drugmakers quickly adopt low-impact AI/ML models in quest to eventually automate manufacturing processes. Already, they are learning a lot about how these models can support their operations. One finding: innovative change management approaches may be required to unlock their full potential.
Did Product Quality Decline While US FDA Inspectors Were Away?
Academics assert more should be done to restore pre-pandemic site-inspection activity levels, especially abroad, following analysis of 10 years of data on US FDA inspection trends, costs and resources published in Health Affairs.
US FDA’s OPQ Reshapes For More Nimble Approach To Drug Quality Reviews
Reorganization in January expected to leave CDER’s nine-year-old pharmaceutical quality assessment organization more adaptable to public health emergencies, new pharmaceutical technologies and market dynamics, while further blending approaches to new and generic drug reviews.